Antisense therapeutics in oncology: Points to consider in their clinical evaluation

Sridhar Mani, Yun Gu, Scott Wadler, Howard Fingert

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Novel therapeutics in oncology stem from a rational design of drugs targeting selective pathways that stimulate and maintain tumor cell growth. Many of these agents are cytostatic in action and also have a limited toxicity profile. However, some can be cytotoxic if they successfully modulate molecular pathways of apoptosis, such as bcl-2. This article discusses points to consider in the design of one class of cytostatic agents, antisense therapy. Our purpose is to stimulate designs that answer the question specifically with regard to proof-of-concept, and the concepts proposed should be viewed as ideas in development rather than firm recommendations.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalAntisense and Nucleic Acid Drug Development
Volume9
Issue number6
DOIs
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Antisense therapeutics in oncology: Points to consider in their clinical evaluation'. Together they form a unique fingerprint.

  • Cite this